Anti-Tdp-43 (N-Terminal Region)

Not available outside of the UK & Ireland.

Application

Anti-TDP-43 (N-terminal region) antibody produced in rabbit has been used in: immunoblotting immunofluorescenceimmunohistochemistry immunuprecipitation

Biochem/physiol Actions

TDP-43 is also involved in mediating the transcription regulation of human immune deficiency virus (HIV). TDP-43 has been identified as the major ubiquinated component of cytoplasmic inclusions in frontotemporal lobe degeneration subtype FTLD-U and amyotrophic lateral sclerosis (ALS). Pathological TDP-43 forms abnormal inclusions in neuronal perikarya and neurites, indicating that redistribution of TDP-43 to the cytoplasm is a pathogenic mechanism. Several pathogenic TDP43 mutations have been identified in familial ALS, causing aberrant cleavage of TDP-43 to C-terminal fragments, and predisposing nuclear TDP-43 to redistribute to the cytoplasm and form pathological aggregates. Abnormal phosphorylation of TDP-43 at Ser409/410 has also been observed in frontotemporal lobar degeneration and amyotrophic lateral sclerosis (FTLD-U and ALS) suggesting a toxic gain of function leading to apoptosis.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

TDP-43 (TAR DNA binding protein, TARDP) belongs to the family of heterogeneous nuclear ribonucleoproteins (hnRNPs) that bind single stranded RNA. TDP-43 is predominantly localized to the nucleus.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.